Clinical Trials Should Include Finding Maintenance Dose, FDA’s Temple Says
This article was originally published in The Pink Sheet Daily
CDER medical policy director says more thorough dose-response work would help reduce drug failure rate, and commends J&J for its study of Risperdal dosing.
You may also be interested in...
FDA is going to fund research projects aimed at eliminating barriers to product development as part of its "critical path" initiative
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.